



Roche Innovation Center Copenhagen A/S

Fremtidsvej 3, 2970 Hørsholm, Denmark

CVR. NO 20 69 00 03

Annual Report for the period 1 January - 31 December 2015

(18th Year of Accounting)

Approved on the Ordinary Annual General Meeting
May 26, 2016

As Chairman

NICOLAS DECAUNAY

This report contains 19 pages incl. frontpage

Content	Page
Statement by the Executive Board and Board of Directors	2
The independent auditors' report	3
Management's review	4
Financial highlights	5
Operating review	6
Financial statements 1 January - 31 December	8
Accounting policies	8
Income statement	12
Balance sheet	13
Development in Equity	15
Notes to the financial statements	16

Statement by the Executive Board and Board of Directors

The Executive Board and Board of Directors have considered and approved the annual report of Roche Innovation Center Copenhagen A/S for 2015.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2015, and of the results of the Company's operations for the financial year 1 January - 31 December 2015.

Further, in our opinion, the Management's review includes a fair review of developments in the Company's operations and financial matters, result for the year and the Company's financial position.

We recommend that the annual report be approved at the annual general meeting.

Hersholm, 26 May 2016

Executive Board:



Jens Bo Rode Hansen
Managing Director

Board of Directors:



John Christian Reed
(Chairman)



Jens Bo Rode Hansen



Ronald Jayung Park



Beal Christoph Krähenmann

The Independent auditors' report

To the shareholder of Roche Innovation Center Copenhagen A/S

Independent auditors' report on the financial statements

We have audited the financial statements of Roche Innovation Center Copenhagen A/S for the financial year 1 January – 31 December 2015. The financial statements comprise income statement, balance sheet, statement of changes of equity and notes, including a summary of significant accounting policies for the Company. The financial statements are prepared in accordance with the Danish Financial Statements Act.

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' responsibility

Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and additional requirements under Danish audit regulation. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Company's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our audit has not resulted in any qualification.

Opinion


In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 January – 31 December 2015 in accordance with the Danish Financial Statements Act.


Statement on the Management's review

Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the Management report is consistent with the financial statements.

Copenhagen, 26 May 2016

KPMG
Statsautoriseret Revisionspartnerselskab
CVR no 25 52 81 78


Lau Bent Boun
State Authorised
Public Accountant


Casper Garrelis
State Authorised
Public Accountant

Management's review

Company details

Roche Innovation Center Copenhagen A/S (RICC A/S)
Fremhidsvej 3
DK-2970 Hørsholm
DENMARK

Telephone:

+45 45 17 98 00

Web site:

http://www.roche.com/research_and_development/who_we_are/how_we_work/rnd_locations/research_location.htm?id=22

Registration No.:

20 69 00 03

Established:

1998

Registered office:

Rudersdal

Board of Directors

John Christian Reed (Chairman)
Jens Bo Rode Hansen
Ronald Jeyung Park
Beat Christoph Krähenmann

Executive Board

Jens Bo Rode Hansen

Auditors

KPMG
Statsautoriseret Revisionspartnerselskab
Dampfærgevej 28
DK-2100 Copenhagen

Annual general meeting

The annual general meeting is to be held on 26 May 2016

Banks

Danske Bank A/S

Financial highlights

	Danish Financial Statements Act		IFRS		
	2015	2014	2013	2012	2011
	TDKK	TDKK	TDKK	TDKK	TDKK
Income Statement					
(1 January - 31 December)					
Gross Profit	174,279	138,204	(2,196)	257,886	17,577
Results from Financial activities	2,483	37,102	(58,709)	(34,103)	3,812
Profit/Loss for the year	1,229,520	(5,462)	(140,925)	(133,146)	(99,761)
Balance Sheet					
(As per 31 December)					
Total Assets	395,859	75,534	161,137	425,385	100,625
hereof:					
Cash and cash equivalents	17	3,132	100,645	45,462	54,109
Trade receivables	2,019	4,515	10,727	336,315	19,809
Intangible assets	0	0	7,219	9,686	12,152
Tangible assets	20,639	3,472	2,367	1,519	2,793
<i>Investment in property, plant and equipment</i>	19,001	3,441	2,278	731	744
Financial assets	3,833	4,270	31,439	32,404	10,797
Total Equity and liabilities	395,859	75,534	161,137	425,385	100,625
hereof:					
Equity	211,537	(67,982)	(167,516)	217,855	63,007
Current Liabilities	145,838	82,992	229,287	148,501	37,618
Non-current liabilities	38,484	60,524	99,365	59,029	-
Financial Ratios					
(As per 31 December)					
Gross margin ratio	78.7%	65.0%	-3.3%	82.5%	26.2%
Net margin ratio	555.5%	-2.6%	-212.8%	-42.6%	-148.5%
Equity ratio	53.4%	-90.0%	-104.0%	51.2%	62.6%

The financial ratios have been prepared in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations and Financial Ratios 2015". For terms and definitions, please see the accounting policies.

With reference to the Danish Financial Statements Act section 51(3), the financial highlights and ratios and comparative figures for 2013 and before have not been adjusted.

Operating review 2015

Roche Innovation Center Copenhagen A/S as part of the Roche Group

F.Hoffmann La Roche Ltd. acquired RICC A/S on August 4th 2014 with the intention to integrate its operations within pharma Early Research & Development organization (pRED) in the Roche Group enabling RICC A/S to continue its research activities in Hørsholm.

In 2015, the Roche Group completed the integration of RICC A/S into pRED. As part of the integration, F.Hoffmann-La Roche Ltd. obtained intellectual properties rights related to the LNA Drug Platform as well as RNA in July 2015 and a contract research agreement enabling RICC to maintain its operations in Denmark has been concluded.

Principal activities

Roche Innovation Center Copenhagen is a leader in the rapidly emerging field of RNA-targeted drugs, where it is exploiting its proprietary Locked Nucleic Acid (LNA) platform to discover important novel medicines across multiple therapeutic areas. Drugs directed against RNA targets have the potential to transform human medicine, making drug discovery, development and manufacture more efficient, faster and less error prone than ever before. At the same time, this novel class of drugs offers the means to address disease targets that have previously been undruggable with conventional drug therapies such as small molecules or antibodies.

Roche is continuously investing in its drug discovery and technology platform, bringing together a multidisciplinary team of scientists with experience, talent and commitment to deliver broadly on the promise of RNA medicines.

Development in activities and financial position

In the context of the integration of RICC A/S into the Roche group, the company's result for 2015 is considered very satisfactory with a profit of DKK 1,230m versus previous year's loss of DKK 5m. This evolution is primarily driven by the conclusion of the aforementioned contract research agreement as well as the assignment of the intellectual properties rights related to the LNA Drug Platform as well as RNA. Subsequently, an extraordinary dividend was paid out to RICC's shareholder in November 2015.

Uncertainties relating to recognition or measurement

In the course of the integration, F. Hoffmann-La Roche Ltd. obtained the rights to the intellectual properties rights related to the LNA Drug Platform as well as RNA.

Management performed an assessment of the fair value of the intellectual property rights applying industry standards as reference. In order to comply with current tax legislation, any contingent component included in the agreed remuneration has been separately valued applying management's best estimate and expertise in the field.

Outlook

The implementation of a contract research agreement between RICC A/S and F. Hoffmann-La Roche Ltd. will secure the financial situation and operating activities of the Company moving forward. Therefore, as part of the Roche group, RICC A/S expects a stable activity level and profit for the coming year.

Risks

The company is not exposed to any special risks besides what are normal risks of the business.

Research and development activities

The RICC team is headed by Bo R. Hansen (Ph.D.) and comprises research groups in chemistry, oligo synthesis, molecular biology, pharmacology, toxicology, PK and bioinformatics.

Effect on the external environment

Management is aware of the external environment and aims to reduce the environmental impact of the company's operations to a minimum.

Human resources and intellectual capital

It is of vital importance when dealing in research, that the employees of the company possess the required scientific expertise. This knowledge is increased and maintained through further education and by recruiting employees with a high level of education and knowledge.

Subsequent events

Since year-end no events have occurred, which could have a significant impact on the Company's financial position.

As of February 2016, Bo R. Hansen has become General Manager of the Company, taking over the role of Henrik Ørum.

Financial statements 1 January - 31 December

Accounting policies

The annual report of Roche Innovation Center Copenhagen A/S for 2015 has been prepared in accordance with the provisions applying to class C-enterprises (medium) under the Danish Financial Statements Act.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

With reference to the Danish Financial Statements Act section 86(4), the cash flow statement is omitted. Instead we refer to the Annual Report for Roche Holding AG, Basel, Switzerland. This can be found on www.roche.com.

The functional currency is DKK and is unchanged compared to prior years.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date.

Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or expense.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognized in the latest consolidated and parent company financial statements is recognized in the income statement as financial income or expense.

Income Statement

Revenue

Income from up-front payments, milestone payments, and other income from research and development contracts is recognized in accordance with the terms of the agreements, when it is considered realized or realizable and earned, when the amount of revenue can be measured reliably, and when the economic benefit associated with the transaction will flow to the company.

The company defers recognition of nonrefundable upfront fees and recognize them into revenue on a straight-line basis over the estimated period of the company's expected performance. The period over which the revenue is recognized may be adjusted to take into account any delays or acceleration in the development of the applicable product candidate or any extension or shortening of the applicable performance period.

Gross profit

With reference to the Danish Financial Statements Act section 32, management decided to aggregate gross revenue and cost of sales and disclose only gross profit.

Cost of sales

Cost of sales comprises costs of sales for the financial year measured at cost, adjusted for ordinary inventory write-downs.

Other external costs

Other external costs comprise expenses of a secondary nature as viewed in relation to the Entity's primary activities such as infrastructure costs, consulting fees, communication and legal costs.

Staff costs

Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.

Research and development costs

Research and development costs include research costs, costs of development projects that do not meet the criteria for recognition in the balance sheet, and amortisation and impairment losses relating to development projects.

Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses relating to intangible assets and property, plant and equipment comprise amortisation, depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets. Impairment tests are performed whenever internal or external indicators suggest that the value of an asset may be impaired. Furthermore, goodwill, indefinite life intangible assets and intangible assets that are not yet ready for use are tested for impairment on an annual basis.

Income from other equity investments and securities

Income from other equity investments and securities comprises realised capital gains and losses from other equity investments and securities recognised or current assets in the balance sheet.

Financial income and expenses

Financial income and expenses comprise interest, realized and unrealized exchange adjustment etc.

Tax on profit/loss for the year

Tax for the year, which consist of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Company is jointly taxed with other Danish associated companies. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

The company participates in a Danish joint taxation arrangement in which Roche A/S (CVR 25230515) serves as the administration company. According to the joint taxation provision rules in the Danish Corporation Tax Act, the company is therefore liable from 2 September 2015 for income taxes etc. obligations, if any, relating to the withholding of tax on interest, royalties and dividends for the jointly taxed companies.

Balance accounts

Intangible assets

Intellectual property rights acquired are measured at cost less accumulated amortisation. Patents are amortized over their remaining duration, and licenses are amortised over the term of the agreement, but over no more than 10 years.

License agreements, Patents and Intellectual property rights etc. are written down to the lower of recoverable amount and carrying amount.

Tangible assets

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided under the straight-line method over the following periods:

Equipment	3 - 10 years
Leasehold Improvement	5 - 10 years
IT & Software	3 - 5 years

Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use. Property, plant and equipment and Leasehold improvements are written down to the lower of recoverable amount and carrying amount.

Gains and losses from disposals of intangible and tangible assets are recognized as other operating income, other operating expenses.

Financial investments

Investments in group enterprises are measured at cost and are written down to the lower of recoverable amount and carrying amount.

Other non-listed financial investments are measured at cost and are written down to the lower of recoverable amount and carrying amount.

Inventories

Inventories are measured at cost in accordance with the FIFO method. Where the net realisable value is lower than cost, inventories are written down to this lower value.

Receivables

Receivables are measured at amortised cost. Write-down is made for bad debt losses based on an individual assessment of receivables.

Prepayments

Prepayments assets, comprise costs incurred concerning subsequent financial years.

Cash and cash equivalents

Cash and cash equivalents comprise cash and short-term marketable securities with a term of three months or less which are subject to an insignificant risk of changes in value. The entity does not hold any short-term marketable securities.

Equity

Dividends

Proposed dividends are recognised as a liability at the date on which they are adopted at the annual general meeting (declaration date). The expected dividend payment for the year is disclosed as a separate line under equity.

Corporation tax and deferred tax

The Company is covered by the Danish rules of compulsory joint taxation of the Roche Groups Danish affiliates. Roche A/S (CVR 25230515) is the administration company for the joint taxation and as such, settles all payments of corporate taxes towards tax authorities.

Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Prepayments received from customers

Prepayments received from customers, if any, comprise amounts received from customers prior to delivery of the goods or service agreed.

Deferred revenue

Deferred revenue comprises received income for recognition in subsequent, financial years. Deferred revenue is measured at cost.

Financial ratios

Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations and Financial Ratios 2015".

The financial ratios stated in the survey of financial highlights have been calculated as follows:

Gross Margin	$\frac{\text{Gross Profit} \times 100}{\text{Revenue}}$
Net margin ratio	$\frac{\text{Profit/Loss for the year} \times 100}{\text{Revenue}}$
Equity ratio	$\frac{\text{Equity at year end} \times 100}{\text{Total equity and liabilities at year end}}$

Income statement

1 January - 31 December 2015

TDKK	Note	2015	2014
Gross profit		174,279	138,204
Staff costs	1	-86,538	-134,171
Research and Development costs		-32,799	-47,577
Depreciation and Amortization		-1,834	-9,335
Operating profit		53,108	-52,878
Income from sale of intangible assets		1,330,729	0
Income from other equity investments	2	7,360	0
Financial income	3	2,524	70,453
Financial expense	4	-41	-33,351
Profit before tax		1,393,680	-15,776
Tax on profit	5	-164,160	10,314
Net Profit/Loss for the year		1,229,520	-5,462
Proposed distribution of profit			
Proposed dividends for financial year		80,000	0
Retained earnings		1,149,520	-5,462
		1,229,520	-5,462

Balance sheet

31 december 2015

TDKK	Note	2015	2014
ASSETS			
Non-current assets			
Licenses and patents	6	0	0
Total intangible assets		<u>0</u>	<u>0</u>
Property, plant and equipment	7	20,639	3,472
Total property, plant and equipment		<u>20,639</u>	<u>3,472</u>
Participating interest in subsidiary		0	612
Other financial investments		0	5
Deposits		3,833	3,653
Total Investments	8	<u>3,833</u>	<u>4,270</u>
Total non-current assets		<u>24,472</u>	<u>7,742</u>
Current assets			
Inventories		8,057	14,345
Total inventories		<u>8,057</u>	<u>14,345</u>
Trade receivables		2,019	4,515
Intercompany receivables		318,254	35,466
TAX receivables		40,892	9,066
Other receivables		2,149	1,254
Prepayments		0	14
Total Receivables		<u>363,314</u>	<u>50,315</u>
Cash at bank and in hand		17	3,132
Total current assets		<u>371,388</u>	<u>67,792</u>
TOTAL ASSETS		<u>395,859</u>	<u>75,534</u>

Balance sheet
31 december 2015

TDKK	Note	2015	2014
EQUITY AND LIABILITIES			
Share capital		100,133	100,133
Retained earnings		31,404	-168,115
Proposed dividend for financial year		80,000	0
Total equity		211,537	-67,982
Liabilities			
Non-current liabilities			
Deferred revenue		38,484	60,524
Total non-current liabilities		38,484	60,524
Current liabilities			
Trade payables		12,572	7,642
Intercompany payables		82,948	28,616
Other payables	9	25,593	8,220
Deferred revenue		24,724	38,514
Total current liabilities		145,838	82,992
Total liabilities		184,322	143,516
TOTAL EQUITY AND LIABILITIES		395,859	75,534
Contingencies, etc.	10		
Related party disclosures	11		

Development in Equity

Equity

	<i>Share Capital</i>	<i>Retained earnings</i>	<i>Proposed dividend for financial year</i>	<i>Total</i>
TDKK				
Equity 1 January 2015	100,133.19	-168,115	0	-67,982
Distributed extraordinary dividend	0	-950,000	0	-950,000
Net profit for the year	0	1,149,520	80,000	1,229,520
Equity 31 December 2015	100,133	31,404	80,000	211,537

The share capital comprises of:	DKK
Share capital A shares of DKK 1.00	14,149,128
Share capital B shares of DKK 1.00	54,100,410
Share capital C shares of DKK 1.00	24,390,601
Share capital D shares of DKK 1.00	7,493,052
	100,133,191

Development in share capital	TDKK
Share capital as per 1 January 2002	1,296
Capital increase 2003	6,062
Capital increase 2006	33,283
Capital increase 2007	44,745
Capital increase 2008	4,549
Capital increase 2009	2
Capital increase 2010	2
Capital increase 2011	2
Capital increase 2014	10,192
Share capital as per 31 December 2015	100,133

Notes to the financial statements

	2015 TDKK	2014 TDKK	
1 Staff Costs			
Wages and salaries	72,525	129,344	
Other social security costs	211	189	
Other staff costs	13,803	4,637	
	<u>84,538</u>	<u>134,171</u>	
Average number of full-time employees	<u>65</u>	<u>58</u>	
Remuneration of the Company's Management and Board of Directors is not disclosed pursuant to section 98b(3)(ii) of the Danish Financial Statements Act.			
2 Income from other equity investments			
The income from other equity investments is related to the 2015 liquidation of the Santaris US subsidiary.			
3 Financial Income			
Automated premium on convertible debentures	0	68,991	
Other financial income	2,524	1,462	
Total financial income	<u>2,524</u>	<u>70,453</u>	
4 Financial costs			
Interests, convertible bonds	0	5,289	
Write-down Investments	0	28,032	
Other financial expenses	41	30	
Total financial costs	<u>41</u>	<u>33,351</u>	
5 Tax on profit			
Current tax	160,774	-9,066	
Adjustment to previous year tax income	3,386	-1,248	
Tax in the year (cost)	<u>164,160</u>	<u>-10,314</u>	
6 Intangible assets			
TDKK	Licenses	Patents	Total
Cost at 1 January 2015	53,235	11,688	64,924
Disposal	-40,134	-200	-40,334
Cost at 31 January 2015	<u>13,102</u>	<u>11,488</u>	<u>24,590</u>
Amortization at 1 January 2015	-53,235	-11,688	-64,924
Amortization	0	0	0
Disposal	40,134	200	40,334
Amortization at 31 December 2015	<u>-13,102</u>	<u>-11,488</u>	<u>-24,590</u>
Carrying amount at 31 December 2015	<u>0</u>	<u>0</u>	<u>0</u>

7 Property, plant and equipment

TDKK	IT & Software	Leasehold Improvement	Equipment	Total
Cost at 1 January 2015	1,398	1,260	19,914	22,572
Additions	201	0	18,800	19,001
Disposal	0	0	-765	-765
Cost at 31 December 2015	1,599	1,260	37,949	40,808
Depreciation at 1 January 2015	-1,367	-1,260	-16,473	-19,100
Depreciation	-55	0	-1,779	-1,834
Disposal	0	0	765	765
Depreciation at 31 December 2015	-1,422	-1,260	-17,487	-20,169
Carrying amount at 31 December 2015	177	0	20,462	20,639
Depreciated over	3-5 years	5-10 years	3-10 years	

8 Financial assets

TDKK	Other financial investments	Deposits	Total
Cost at 1 January 2015	5	3,653	3,658
Additions	0	180	180
Cost at 31 December 2015	5	3,833	3,838
Depreciation at 1 January 2015	0	0	0
Disposal	-5	0	-5
Depreciation at 31 December 2015	-5	0	-5
Carrying amount at 31 December 2015	0	3,833	3,833

9 Other Payables

	2015 TDKK	2014 TDKK
Employee related compensation and benefits	22,729	6,530
Other	2,864	1,690
	25,593	8,220

10 Contingencies, etc.

Lease obligations

The Company has entered into operating leases regarding car and other equipments. The remaining payments for lease obligations amount to DKK 540 thousand (2014: DKK 137 thousand) of which DKK 255 thousand is due within the next 12 months.

Rent obligations

The Company leases office space and laboratory space under cancellable operation lease agreement, subject to a 6 months notification period. Therefore, a lease term of six months is considered as the company's commitment which equals DKK 3,836 thousands as of December 31, 2015 for a yearly rent of DKK 7,672 thousands.

Law suits

Roche Innovation Center Copenhagen A/S is RICC is not involved in any law suit.

Tax obligations

The company participates in a Danish joint taxation arrangement in which, Roche A/S (CVR 25230515) serves as the administration company. According to the joint taxation provision rules in the Danish Corporation Tax Act, the company is therefore liable from 2 September 2014 for income taxes etc., obligations, if any, relating to the withholding of tax on interest, royalties and dividends for the jointly taxed companies.

11 Related party disclosures

Roche Innovation Center Copenhagen A/S related parties comprise:

Parties exercising control

Roche Innovation Center Copenhagen A/S is owned 100% by F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland. The Company is included in the consolidated financial statement of Roche Holding Ltd, Grenzacherstrasse 124, 4070 Basel, the ultimate shareholder of the Group. The consolidated financial statements of Roche Holding Ltd. are available at the Company's address or on the Company's website at www.roche.com.

Other related parties with significant influence

Group enterprises and associates of F. Hoffmann-La Roche Ltd. Related parties exercising significant influence furthermore comprise the Company's Board of Directors and executive employees. Further, related parties comprise companies in which the above persons have substantial interest.